Search

Your search keyword '"Gras, Luuk"' showing total 6 results
Start Over Author "Gras, Luuk" Journal american journal of hematology
6 results on '"Gras, Luuk"'

1. Outcomes of CMML patients undergoing allo‐HCT are significantly worse compared to MDS—a study of the CMWP of the EBMT

Author

Rovó, Alicia, primary, Gras, Luuk, additional, Piepenbroek, Brian, additional, Kröger, Nicolaus, additional, Reinhardt, H. Christian, additional, Radujkovic, Aleksandar, additional, Blaise, Didier, additional, Kobbe, Guido, additional, Niityvuopio, Riitta, additional, Platzbecker, Uwe, additional, Sockel, Katja, additional, Hunault‐Berger, Mathilde, additional, Cornelissen, J. J., additional, Forcade, Edouard, additional, Bourhis, Jean Henri, additional, Chalandon, Yves, additional, Kinsella, Francesca, additional, Nguyen‐Quoc, Stéphanie, additional, Maertens, Johan, additional, Elmaagacli, Ahmet, additional, Mordini, Nicola, additional, Hayden, Patrick, additional, Raj, Kavita, additional, Drozd‐Sokolowska, Joanna, additional, de Wreede, Liesbeth C., additional, McLornan, Donal P., additional, Robin, Marie, additional, Yakoub‐Agha, Ibrahim, additional, and Onida, Francesco, additional

Published
2023
Full Text
View/download PDF

2. Outcomes of CMML patients undergoing allo‐HCT are significantly worse compared to MDS—a study of the CMWP of the EBMT.

Author

Rovó, Alicia, Gras, Luuk, Piepenbroek, Brian, Kröger, Nicolaus, Reinhardt, H. Christian, Radujkovic, Aleksandar, Blaise, Didier, Kobbe, Guido, Niityvuopio, Riitta, Platzbecker, Uwe, Sockel, Katja, Hunault‐Berger, Mathilde, Cornelissen, J. J., Forcade, Edouard, Bourhis, Jean Henri, Chalandon, Yves, Kinsella, Francesca, Nguyen‐Quoc, Stéphanie, Maertens, Johan, and Elmaagacli, Ahmet

Published
2024
Full Text
View/download PDF

3. Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Author

Ortí, Guillermo, primary, Gras, Luuk, additional, Zinger, Nienke, additional, Finazzi, Maria Chiara, additional, Sockel, Katja, additional, Robin, Marie, additional, Forcade, Edouard, additional, Avenoso, Daniele, additional, Kröger, Nicolaus, additional, Finke, Jürgen, additional, Radujkovic, Aleksandar, additional, Hunault‐Berger, Mathilde, additional, Schroyens, Wilfried, additional, Zuckerman, Tsila, additional, Bourhis, Jean Henri, additional, Chalandon, Yves, additional, Bloor, Adrian, additional, Schots, Rik, additional, de Wreede, Liesbeth C., additional, Drozd‐Sokolowska, Joana, additional, Raj, Kavita, additional, Polverelli, Nicola, additional, Czerw, Tomasz, additional, Hernández‐Boluda, Juan Carlos, additional, McLornan, Donal, additional, and Yakoub‐Agha, Ibrahim, additional

Published
2023
Full Text
View/download PDF

4. Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT.

Author

Chalandon, Yves, Sbianchi, Giulia, Gras, Luuk, Koster, Linda, Apperley, Jane, Byrne, Jenny, Salmenniemi, Urpu, Sengeloev, Henrik, Aljurf, Mahmoud, Helbig, Grzegorz, Kinsella, Francesca, Choi, Goda, Reményi, Péter, Snowden, John A., Robin, Marie, Lenhoff, Stig, Mielke, Stephan, Passweg, Jakob, Broers, Annoek E. C., and Kröger, Nicolaus

Published
2023
Full Text
View/download PDF

5. Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry

Author

Hernández‐Boluda, Juan‐Carlos, primary, Pereira, Arturo, additional, Kröger, Nicolaus, additional, Cornelissen, Jan J., additional, Finke, Jürgen, additional, Beelen, Dietrich, additional, de Witte, Moniek, additional, Wilson, Keith, additional, Platzbecker, Uwe, additional, Sengeloev, Henrik, additional, Blaise, Didier, additional, Einsele, Hermann, additional, Sockel, Katja, additional, Krüger, William, additional, Lenhoff, Stig, additional, Salaroli, Adriano, additional, Martin, Hans, additional, García‐Gutiérrez, Valentín, additional, Pavone, Vicenzo, additional, Alvarez‐Larrán, Alberto, additional, Raya, José‐María, additional, Zinger, Nienke, additional, Gras, Luuk, additional, Hayden, Patrick, additional, Czerw, Tomasz, additional, P. McLornan, Donal, additional, and Yakoub‐Agha, Ibrahim, additional

Published
2021
Full Text
View/download PDF

6. Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT).

Author

Garderet L, Gras L, Koster L, Baaij L, Hamad N, Dsouza A, Estrada-Merly N, Hari P, Saber W, Cowan AJ, Iida M, Okamoto S, Takamatsu H, Mizuno S, Kawamura K, Kodera Y, Ko BS, Liam C, Ho KW, Goh AS, Tan SK, Elhaddad AM, Bazarbachi A, Chaudhry QUN, Alfar R, Bekadja MA, Benakli M, Ortiz CAF, Riva E, Galeano S, Bass F, Mian HS, McCurdy A, Wang FR, Meng L, Neumann D, Koh M, Snowden JA, Schönland S, McLornan DP, Hayden PJ, Sureda A, Greinix HT, Aljurf M, Atsuta Y, and Niederwieser D

Subjects
Humans, Middle Aged, Male, Female, Aged, Adult, Registries, Treatment Outcome, Lenalidomide therapeutic use, Lenalidomide administration & dosage, Survival Rate, Multiple Myeloma therapy, Multiple Myeloma mortality, Hematopoietic Stem Cell Transplantation, Transplantation, Autologous
Abstract

Autologous hematopoietic cell transplantation (AHCT) is a commonly used treatment in multiple myeloma (MM). However, real-world global demographic and outcome data are scarce. We collected data on baseline characteristics and outcomes from 61 725 patients with newly diagnosed MM who underwent upfront AHCT between 2013 and 2017 from nine national/international registries. The primary endpoint was overall survival (OS), and the secondary endpoints were progression-free survival (PFS), relapse incidence (RI) and non-relapse mortality (NRM). Median OS amounted to 90.2 months (95% CI 88.2-93.6) and median PFS 36.5 months (95% CI 36.1-37.0). At 24 months, cumulative RI was 33% (95% CI 32.5%-33.4%) and NRM was 2.5% (95% CI 2.3%-2.6%). In the multivariate analysis, superior outcomes were associated with younger age, IgG subtype, complete hematological response at auto-HCT, Karnofsky score of 100%, international staging scoring (ISS) stage 1, HCT-comorbidity index (CI) 0, standard cytogenetic risk, auto-HCT in recent years, and use of lenalidomide maintenance. There were differences in the baseline characteristics and outcomes between registries. While the NRM was 1%-3% at 12 months worldwide, the OS at 36 months was 69%-84%, RI at 12 months was 12%-24% and PFS at 36 months was 43%-63%. The variability in these outcomes is attributable to differences in patient and disease characteristics as well as the use of maintenance and macroeconomic factors. In conclusion, worldwide data indicate that AHCT in MM is a safe and effective therapy with an NRM of 1%-3% with considerable regional differences in OS, PFS, RI, and patient characteristics. Maintenance treatment post-AHCT had a beneficial effect on OS., (© 2024 The Author(s). American Journal of Hematology published by Wiley Periodicals LLC.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results